The role of microRNAs in gallbladder cancer (Review)
- Authors:
- Ganghua Yang
- Lei Zhang
- Ruixiang Li
- Lin Wang
-
Affiliations: Department of Geriatric Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China - Published online on: May 11, 2016 https://doi.org/10.3892/mco.2016.905
- Pages: 7-13
This article is mentioned in:
Abstract
Hundal R and Shaffer EA: Gallbladder cancer: Epidemiology and outcome. Clin Epidemiol. 6:99–109. 2014.PubMed/NCBI | |
Lazcano-Ponce EC, Miquel JF, Muñoz N, Herrero R, Ferrecio C, Wistuba II, de Alonso Ruiz P, Aristi Urista G and Nervi F: Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 51:349–364. 2001. View Article : Google Scholar : PubMed/NCBI | |
Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI | |
Ding Q, Li M, Wu X, Zhang L, Wu W, Ding Q, Weng H, Wang X and Liu Y: CLIC1 overexpression is associated with poor prognosis in gallbladder cancer. Tumour Biol. 36:193–198. 2015. View Article : Google Scholar : PubMed/NCBI | |
Chen L, Wang J, Fu L, Zhang B, Zhang H and Ye B: Prognostic significance of metastasis associated in colon cancer 1 (MACC1) expression in patients with gallbladder cancer. J Cancer Res Ther. 10:1052–1056. 2014. View Article : Google Scholar : PubMed/NCBI | |
Nigam J, Chandra A, Kazmi HR, Parmar D, Singh D and Gupta V: Prognostic significance of survivin in resected gallbladder cancer. J Surg Res. 194:57–62. 2015. View Article : Google Scholar : PubMed/NCBI | |
Groot Koerkamp B and Fong Y: Outcomes in biliary malignancy. J Surg Oncol. 110:585–591. 2014. View Article : Google Scholar : PubMed/NCBI | |
Wang J, Narang AK, Sugar EA, Luber B, Rosati LM, Hsu CC, Fuller CD, Pawlik TM, Miller RC, Czito BG, et al: Evaluation of adjuvant radiation therapy for resected gallbladder carcinoma: A multi-institutional experience. Ann Surg Oncol. 2015. | |
Weatherall TJ, Fenton M, Munene G, Dickson PV and Deneve JL: Locally advanced, unresectable squamous cell carcinoma of the gallbladder. Case Rep Surg. 2015:4246502015.PubMed/NCBI | |
Yang XW, Yuan JM, Chen JY, Yang J, Gao QG, Yan XZ, Zhang BH, Feng S and Wu MC: The prognostic importance of jaundice in surgical resection with curative intent for gallbladder cancer. BMC Cancer. 14:6522014. View Article : Google Scholar : PubMed/NCBI | |
Niu GC, Shen CM, Cui W and Li Q: Surgical treatment of advanced gallbladder cancer. Am J Clin Oncol. 38:5–10. 2015. View Article : Google Scholar : PubMed/NCBI | |
Higuchi R, Ota T, Araida T, Kajiyama H, Yazawa T, Furukawa T, Yoshikawa T, Takasaki K and Yamamoto M: Surgical approaches to advanced gallbladder cancer: A 40-year single-institution study of prognostic factors and resectability. Ann Surg Oncol. 21:4308–4316. 2014. View Article : Google Scholar : PubMed/NCBI | |
Park JO, Oh DY, Hsu C, Chen JS, Chen LT, Orlando M, Kim JS and Lim HY: Gemcitabine plus cisplatin for advanced biliary tract cancer: A systematic review. Cancer Res Treat. 47:343–361. 2015. View Article : Google Scholar : PubMed/NCBI | |
Alberts SR, Al-Khatib H, Mahoney MR, Burgart L, Cera PJ, Flynn PJ, Finch TR, Levitt R, Windschitl HE, Knost JA and Tschetter LK: Gemcitabine, 5-fluorouracil and leucovorin in advanced biliary tract and gallbladder carcinoma: A North Central Cancer Treatment Group phase II trial. Cancer. 103:111–118. 2005. View Article : Google Scholar : PubMed/NCBI | |
Ueno H, Okusaka T, Ikeda M, Takezako Y and Morizane C: Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer. 91:1769–1774. 2004. View Article : Google Scholar : PubMed/NCBI | |
Saito H, Takada T, Miyazaki M, Miyakawa S, Tsukada K, Nagino M, Kondo S, Furuse J, Tsuyuguchi T, Kimura F, et al: Radiation therapy and photodynamic therapy for biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg. 15:63–68. 2008. View Article : Google Scholar : PubMed/NCBI | |
Ohtsuka M, Ling H, Doki Y, Mori M and Calin GA: MicroRNA processing and human cancer. J Clin Med. 4:1651–1667. 2015. View Article : Google Scholar : PubMed/NCBI | |
Wang J, Du Y, Liu X, Cho WC and Yang Y: MicroRNAs as regulator of signaling networks in metastatic colon cancer. Biomed Res Int. 2015:8236202015.PubMed/NCBI | |
Orellana EA and Kasinski AL: MicroRNAs in cancer: A historical perspective on the path from discovery to therapy. Cancers (Basel). 7:1388–1405. 2015. View Article : Google Scholar : PubMed/NCBI | |
Bertoli G, Cava C and Castiglioni I: MicroRNAs: New biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics. 5:1122–1143. 2015. View Article : Google Scholar : PubMed/NCBI | |
Kishikawa T, Otsuka M, Ohno M, Yoshikawa T, Takata A and Koike K: Circulating RNAs as new biomarkers for detecting pancreatic cancer. World J Gastroenterol. 21:8527–8540. 2015. View Article : Google Scholar : PubMed/NCBI | |
Kelly BD, Miller N, Sweeney KJ, Durkan GC, Rogers E, Walsh K and Kerin MJ: A circulating microRNA signature as a biomarker for prostate cancer in a high-risk group. J Clin Med. 4:1369–1379. 2015. View Article : Google Scholar : PubMed/NCBI | |
Jia W, Wu Y, Zhang Q, Gao GE, Zhang C and Xiang Y: Expression profile of circulating microRNAs as a promising fingerprint for cervical cancer diagnosis and monitoring. Mol Clin Oncol. 3:851–858. 2015.PubMed/NCBI | |
Karimi Kurdistani Z, Saberi S, Tsai KW and Mohammadi M: MicroRNA-21: Mechanisms of oncogenesis and its application in diagnosis and prognosis of gastric cancer. Arch Iran Med. 18:524–536. 2015.PubMed/NCBI | |
Fang Z, Tang J, Bai Y, Lin H, You H, Jin H, Lin L, You P, Li J, Dai Z, et al: Plasma levels of microRNA-24, microRNA-320a and microRNA-423-5p are potential biomarkers for colorectal carcinoma. J Exp Clin Cancer Res. 34:862015. View Article : Google Scholar : PubMed/NCBI | |
Li G and Pu Y: MicroRNA signatures in total peripheral blood of gallbladder cancer patients. Tumour Biol. 36:6985–6990. 2015. View Article : Google Scholar : PubMed/NCBI | |
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI | |
Di Leva G and Croce CM: miRNA profiling of cancer. Curr Opin Genet Dev. 23:3–11. 2013. View Article : Google Scholar : PubMed/NCBI | |
Lee RC, Feinbaum RL and Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI | |
Peterson SM, Thompson JA, Ufkin ML, Sathyanarayana P, Liaw L and Congdon CB: Common features of microRNA target prediction tools. Front Genet. 5:232014. View Article : Google Scholar : PubMed/NCBI | |
Galli V, Guzman F, de Oliveira LF, Loss-Morais G, Körbes AP, Silva SD, Margis-Pinheiro MM and Margis R: Identifying microRNAs and transcript targets in Jatropha seeds. PLoS One. 9:e837272014. View Article : Google Scholar : PubMed/NCBI | |
Liu B, Li J and Cairns MJ: Identifying miRNAs, targets and functions. Brief Bioinform. 15:1–19. 2014. View Article : Google Scholar : PubMed/NCBI | |
Shi Q and Yang X: Circulating microRNA and long noncoding RNA as biomarkers of cardiovascular diseases. J Cell Physiol. 2015. | |
Ha TY: MicroRNAs in human diseases: From lung, liver and kidney diseases to infectious disease, sickle cell disease and endometrium disease. Immune Netw. 11:309–323. 2011. View Article : Google Scholar : PubMed/NCBI | |
Srivastava SP, Koya D and Kanasaki K: MicroRNAs in kidney fibrosis and diabetic nephropathy: Roles on EMT and EndMT. Biomed Res Int. 2013:1254692013. View Article : Google Scholar : PubMed/NCBI | |
Bekris LM and Leverenz JB: The biomarker and therapeutic potential of miRNA in Alzheimer's disease. Neurodegener Dis Manag. 5:61–74. 2015. View Article : Google Scholar : PubMed/NCBI | |
Kumar Shamsuzzama L, Haque R and Nazir A: Role of microRNA Let-7 in modulating multifactorial aspect of neurodegenerative diseases: An overview. Mol Neurobiol. 2015.(Epub ahead of print). | |
Xue J, Chen Z, Gu X, Zhang Y and Zhang W: MicroRNA-148a inhibits migration of breast cancer cells by targeting MMP-13. Tumour Biol. 2015.(Epub ahead of print). | |
Tong Z, Liu N, Lin L, Guo X, Yang D and Zhang Q: miR-125a-5p inhibits cell proliferation and induces apoptosis in colon cancer via targeting BCL2, BCL2L12 and MCL1. Biomed Pharmacother. 75:129–136. 2015. View Article : Google Scholar : PubMed/NCBI | |
Li W, Zhang J, Chen T, Yin P, Yang J and Cao Y: MiR-132 upregulation promotes gastric cancer cell growth through suppression of FoxO1 translation. Tumour Biol. 2015. | |
Farra R, Grassi M, Grassi G and Dapas B: Therapeutic potential of small interfering RNAs/micro interfering RNA in hepatocellular carcinoma. World J Gastroenterol. 21:8994–9001. 2015. View Article : Google Scholar : PubMed/NCBI | |
Srivastava K, Srivastava A and Mittal B: Common genetic variants in pre-microRNAs and risk of gallbladder cancer in North Indian population. J Hum Genet. 55:495–499. 2010. View Article : Google Scholar : PubMed/NCBI | |
Kono H, Nakamura M, Ohtsuka T, Nagayoshi Y, Mori Y, Takahata S, Aishima S and Tanaka M: High expression of microRNA-155 is associated with the aggressive malignant behavior of gallbladder carcinoma. Oncol Rep. 30:17–24. 2013.PubMed/NCBI | |
Peng HH, Zhang YD, Gong LS, Liu WD and Zhang Y: Increased expression of microRNA-335 predicts a favorable prognosis in primary gallbladder carcinoma. Onco Targets Ther. 6:1625–1630. 2013.PubMed/NCBI | |
Li Z, Yu X, Shen J, Law PT, Chan MT and Wu WK: MicroRNA expression and its implications for diagnosis and therapy of gallbladder cancer. Oncotarget. 6:13914–13921. 2015. View Article : Google Scholar : PubMed/NCBI | |
Zhou H, Guo W, Zhao Y, Wang Y, Zha R, Ding J, Liang L, Hu J, Shen H, Chen Z, et al: MicroRNA-26a acts as a tumor suppressor inhibiting gallbladder cancer cell proliferation by directly targeting HMGA2. Int J Oncol. 44:2050–2058. 2014.PubMed/NCBI | |
Zhou H, Guo W, Zhao Y, Wang Y, Zha R, Ding J, Liang L, Yang G, Chen Z, Ma B and Yin B: MicroRNA-135a acts as a putative tumor suppressor by directly targeting very low density lipoprotein receptor in human gallbladder cancer. Cancer Sci. 105:956–965. 2014. View Article : Google Scholar : PubMed/NCBI | |
Letelier P, García P, Leal P, Álvarez H, Ili C, López J, Castillo J, Brebi P and Roa JC: miR-1 and miR-145 act as tumor suppressor microRNAs in gallbladder cancer. Int J Clin Exp Pathol. 7:1849–1867, eCollection 2014. 2014.PubMed/NCBI | |
Chan JA, Krichevsky AM and Kosik KS: MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 65:6029–6033. 2005. View Article : Google Scholar : PubMed/NCBI | |
Lin PL, Wu DW, Huang CC, He TY, Chou MC, Sheu GT and Lee H: MicroRNA-21 promotes tumour malignancy via increased nuclear translocation of β-catenin and predicts poor outcome in APC-mutated but not in APC-wild-type colorectal cancer. Carcinogenesis. 35:2175–2182. 2014. View Article : Google Scholar : PubMed/NCBI | |
Guo Q, Zhang H, Zhang L, He Y, Weng S, Dong Z, Wang J, Zhang P and Nao R: MicroRNA-21 regulates non-small cell lung cancer cell proliferation by affecting cell apoptosis via COX-19. Int J Clin Exp Med. 8:8835–8841, eCollection 2015. 2015.PubMed/NCBI | |
Lu L, Byrnes K, Han C, Wang Y and Wu T: miR-21 targets 15-PGDH and promotes cholangiocarcinoma growth. Mol Cancer Res. 12:890–900. 2014. View Article : Google Scholar : PubMed/NCBI | |
Kitamura T, Connolly K, Ruffino L, Ajiki T, Lueckgen A, DiGiovanni J and Kiguchi K: The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice. J Hepatol. 57:84–91. 2012. View Article : Google Scholar : PubMed/NCBI | |
Sekine S, Shimada Y, Nagata T, Sawada S, Yoshioka I, Matsui K, Moriyama M, Omura T, Osawa S, Shibuya K, et al: Role of aquaporin-5 in gallbladder carcinoma. Eur Surg Res. 51:108–117. 2013. View Article : Google Scholar : PubMed/NCBI | |
Zhao S, Yao D, Chen J and Ding N: Circulating miRNA-20a and miRNA-203 for screening lymph node metastasis in early stage cervical cancer. Genet Test Mol Biomarkers. 17:631–636. 2013. View Article : Google Scholar : PubMed/NCBI | |
Mitani Y, Roberts DB, Fatani H, Weber RS, Kies MS, Lippman SM and El-Naggar AK: MicroRNA profiling of salivary adenoid cystic carcinoma: Association of miR-17-92 upregulation with poor outcome. PLoS One. 8:e667782013. View Article : Google Scholar : PubMed/NCBI | |
Wu Q, Yang Z, Wang F, Hu S, Yang L, Shi Y and Fan D: miR-19b/20a/92a regulates the self-renewal and proliferation of gastric cancer stem cells. J Cell Sci. 126:4220–4229. 2013. View Article : Google Scholar : PubMed/NCBI | |
Xiong Y, Zhang L and Kebebew E: miR-20a is upregulated in anaplastic thyroid cancer and targets LIMK1. PLoS One. 9:e961032014. View Article : Google Scholar : PubMed/NCBI | |
Qiang XF, Zhang ZW, Liu Q, Sun N, Pan LL, Shen J, Li T, Yun C, Li H and Shi LH: miR-20a promotes prostate cancer invasion and migration through targeting ABL2. J Cell Biochem. 115:1269–1276. 2014. View Article : Google Scholar : PubMed/NCBI | |
Chang Y, Liu C, Yang J, Liu G, Feng F, Tang J, Hu L, Li L, Jiang F, Chen C, et al: miR-20a triggers metastasis of gallbladder carcinoma. J Hepatol. 59:518–527. 2013. View Article : Google Scholar : PubMed/NCBI | |
Osaka E, Kelly AD, Spentzos D, Choy E, Yang X, Shen JK, Yang P, Mankin HJ, Hornicek FJ and Duan Z: MicroRNA-155 expression is independently predictive of outcome in chordoma. Oncotarget. 6:9125–9139. 2015. View Article : Google Scholar : PubMed/NCBI | |
Peng Y, Dong W, Lin TX, Zhong GZ, Liao B, Wang B, Gu P, Huang L, Xie Y, Lu FD, et al: MicroRNA-155 promotes bladder cancer growth by repressing the tumor suppressor DMTF1. Oncotarget. 6:16043–16058. 2015. View Article : Google Scholar : PubMed/NCBI | |
Wang P, Zhu CF, Ma MZ, Chen G, Song M, Zeng ZL, Lu WH, Yang J, Wen S, Chiao PJ, et al: Micro-RNA-155 is induced by K-Ras oncogenic signal and promotes ROS stress in pancreatic cancer. Oncotarget. 6:21148–21158. 2015. View Article : Google Scholar : PubMed/NCBI | |
Gasparini P, Cascione L, Fassan M, Lovat F, Guler G, Balci S, Irkkan C, Morrison C, Croce CM, Shapiro CL and Huebner K: MicroRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget. 5:1174–1184. 2014. View Article : Google Scholar : PubMed/NCBI | |
Wang PY, Gong HT, Li BF, Lv CL, Wang HT, Zhou HH, Li XX, Xie SY and Jiang BF: Higher expression of circulating miR-182 as a novel biomarker for breast cancer. Oncol Lett. 6:1681–1686. 2013.PubMed/NCBI | |
Du C, Weng X, Hu W, Lv Z, Xiao H, Ding C, Gyabaah OA, Xie H, Zhou L, Wu J and Zheng S: Hypoxia-inducible miR-182 promotes angiogenesis by targeting RASA1 in hepatocellular carcinoma. J Exp Clin Cancer Res. 34:672015. View Article : Google Scholar : PubMed/NCBI | |
Jiang L, Mao P, Song L, Wu J, Huang J, Lin C, Yuan J, Qu L, Cheng SY and Li J: miR-182 as a prognostic marker for glioma progression and patient survival. Am J Pathol. 177:29–38. 2010. View Article : Google Scholar : PubMed/NCBI | |
Liu R, Li J, Teng Z, Zhang Z and Xu Y: Overexpressed microRNA-182 promotes proliferation and invasion in prostate cancer PC-3 cells by down-regulating N-myc downstream regulated gene 1 (NDRG1). PLoS One. 8:e689822013. View Article : Google Scholar : PubMed/NCBI | |
Qiu Y, Luo X, Kan T, Zhang Y, Yu W, Wei Y, Shen N, Yi B and Jiang X: TGF-β upregulates miR-182 expression to promote gallbladder cancer metastasis by targeting CADM1. Mol Biosyst. 10:679–685. 2014. View Article : Google Scholar : PubMed/NCBI | |
Yu J, Wang Y, Dong R, Huang X, Ding S and Qiu H: Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor invasion. J Cancer Res Clin Oncol. 138:671–674. 2012. View Article : Google Scholar : PubMed/NCBI | |
Cheng Y, Yang X, Deng X, Zhang X, Li P, Tao J and Lu Q: MicroRNA-218 inhibits bladder cancer cell proliferation, migration and invasion by targeting BMI-1. Tumour Biol. 36:8015–8023. 2015. View Article : Google Scholar : PubMed/NCBI | |
Han G, Fan M and Zhang X: MicroRNA-218 inhibits prostate cancer cell growth and promotes apoptosis by repressing TPD52 expression. Biochem Biophys Res Commun. 456:804–809. 2015. View Article : Google Scholar : PubMed/NCBI | |
Liu Z, Xu Y, Long J, Guo K, Ge C and Du R: MicroRNA-218 suppresses the proliferation, invasion and promotes apoptosis of pancreatic cancer cells by targeting HMGB1. Chin J Cancer Res. 27:247–257. 2015.PubMed/NCBI | |
Tian H, Hou L, Xiong YM, Huang JX, She YJ, Bi XB and Song XR: miR-218 suppresses tumor growth and enhances the chemosensitivity of esophageal squamous cell carcinoma to cisplatin. Oncol Rep. 33:981–989. 2015.PubMed/NCBI | |
Ma MZ, Chu BF, Zhang Y, Weng MZ, Qin YY, Gong W and Quan ZW: Long non-coding RNA CCAT1 promotes gallbladder cancer development via negative modulation of miRNA-218-5p. Cell Death Dis. 6:e15832015. View Article : Google Scholar : PubMed/NCBI | |
Zu Y, Ban J, Xia Z, Wang J, Cai Y, Ping W and Sun W: Genetic variation in a miR-335 binding site in BIRC5 alters susceptibility to lung cancer in Chinese Han populations. Biochem Biophys Res Commun. 430:529–534. 2013. View Article : Google Scholar : PubMed/NCBI | |
Dohi O, Yasui K, Gen Y, Takada H, Endo M, Tsuji K, Konishi C, Yamada N, Mitsuyoshi H, Yagi N, et al: Epigenetic silencing of miR-335 and its host gene MEST in hepatocellular carcinoma. Int J Oncol. 42:411–418. 2013.PubMed/NCBI | |
Xu Y, Zhao F, Wang Z, Song Y, Luo Y, Zhang X, Jiang L, Sun Z, Miao Z and Xu H: MicroRNA-335 acts as a metastasis suppressor in gastric cancer by targeting Bcl-w and specificity protein 1. Oncogene. 31:1398–1407. 2012. View Article : Google Scholar : PubMed/NCBI | |
Sun Z, Zhang Z, Liu Z, Qiu B, Liu K and Dong G: MicroRNA-335 inhibits invasion and metastasis of colorectal cancer by targeting ZEB2. Med Oncol. 31:9822014. View Article : Google Scholar : PubMed/NCBI | |
Gao L, Yang Y, Xu H, Liu R, Li D, Hong H, Qin M and Wang Y: miR-335 functions as a tumor suppressor in pancreatic cancer by targeting OCT4. Tumour Biol. 35:8309–8318. 2014. View Article : Google Scholar : PubMed/NCBI | |
Li XJ, Ren ZJ and Tang JH: MicroRNA-34a: A potential therapeutic target in human cancer. Cell Death Dis. 5:e13272014. View Article : Google Scholar : PubMed/NCBI | |
Jin K, Xiang Y, Tang J, Wu G, Li J, Xiao H, Li C, Chen Y and Zhao J: miR-34 is associated with poor prognosis of patients with gallbladder cancer through regulating telomere length in tumor stem cells. Tumour Biol. 35:1503–1510. 2014. View Article : Google Scholar : PubMed/NCBI | |
Basu N, Skinner HG, Litzelman K, Vanderboom R, Baichoo E and Boardman LA: Telomeres and telomere dynamics: Relevance to cancers of the GI tract. Expert Rev Gastroenterol Hepatol. 7:733–748. 2013. View Article : Google Scholar : PubMed/NCBI | |
Pan Y, Wang R, Zhang F, Chen Y, Lv Q, Long G and Yang K: MicroRNA-130a inhibits cell proliferation, invasion and migration in human breast cancer by targeting the RAB5A. Int J Clin Exp Pathol. 8:384–393, eCollection 2015. 2015.PubMed/NCBI | |
Li B, Huang P, Qiu J, Liao Y, Hong J and Yuan Y: MicroRNA-130a is down-regulated in hepatocellular carcinoma and associates with poor prognosis. Med Oncol. 31:2302014. View Article : Google Scholar : PubMed/NCBI | |
Ma MZ, Li CX, Zhang Y, Weng MZ, Zhang MD, Qin YY, Gong W and Quan ZW: Long non-coding RNA HOTAIR, a c-Myc activated driver of malignancy, negatively regulates miRNA-130a in gallbladder cancer. Mol Cancer. 13:1562014. View Article : Google Scholar : PubMed/NCBI | |
Dang Z, Xu WH, Lu P, Wu N, Liu J, Ruan B, Zhou L, Song WJ and Dou KF: MicroRNA-135a inhibits cell proliferation by targeting Bmi1 in pancreatic ductal adenocarcinoma. Int J Biol Sci. 10:733–745. 2014. View Article : Google Scholar : PubMed/NCBI | |
Shin JY, Kim YI, Cho SJ, Lee MK, Kook MC, Lee JH, Lee SS, Ashktorab H, Smoot DT, Ryu KW, et al: MicroRNA 135a suppresses lymph node metastasis through down-regulation of ROCK1 in early gastric cancer. PLoS One. 9:e852052014. View Article : Google Scholar : PubMed/NCBI | |
Tang W, Jiang Y, Mu X, Xu L, Cheng W and Wang X: miR-135a functions as a tumor suppressor in epithelial ovarian cancer and regulates HOXA10 expression. Cell Signal. 26:1420–1426. 2014. View Article : Google Scholar : PubMed/NCBI | |
Yang X, Zhang XF, Lu X, Jia HL, Liang L, Dong QZ, Ye QH and Qin LX: MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway. Hepatology. 59:1874–1885. 2014. View Article : Google Scholar : PubMed/NCBI | |
Liu P, Tang H, Chen B, He Z, Deng M, Wu M, Liu X, Yang L, Ye F and Xie X: miR-26a suppresses tumour proliferation and metastasis by targeting metadherin in triple negative breast cancer. Cancer Lett. 357:384–392. 2015. View Article : Google Scholar : PubMed/NCBI | |
Shen C, Yang H, Liu H, Wang X, Zhang Y and Xu R: Inhibitory effect and mechanisms of microRNA-146b-5p on the proliferation and metastatic potential of Caski human cervical cancer cells. Mol Med Rep. 11:3955–3961. 2015.PubMed/NCBI | |
Lin F, Wang X, Jie Z, Hong X, Li X, Wang M and Yu Y: Inhibitory effects of miR-146b-5p on cell migration and invasion of pancreatic cancer by targeting MMP16. J Huazhong Univ Sci Technolog Med Sci. 31:509–514. 2011. View Article : Google Scholar : PubMed/NCBI | |
Wu PY, Zhang XD, Zhu J, Guo XY and Wang JF: Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone. Hum Pathol. 45:1664–1673. 2014. View Article : Google Scholar : PubMed/NCBI | |
Katakowski M, Zheng X, Jiang F, Rogers T, Szalad A and Chopp M: miR-146b-5p suppresses EGFR expression and reduces in vitro migration and invasion of glioma. Cancer Invest. 28:1024–1030. 2010. View Article : Google Scholar : PubMed/NCBI | |
Cai J, Xu L, Cai Z, Wang J, Zhou B and Hu H: MicroRNA-146b-5p inhibits the growth of gallbladder carcinoma by targeting epidermal growth factor receptor. Mol Med Rep. 12:1549–1555. 2015.PubMed/NCBI | |
Gupta A, Sharma A, Yadav A, Rastogi N, Agrawal S, Kumar A, Kumar V, Misra S and Mittal B: Evaluation of miR-27a, miR-181a and miR-570 genetic variants with gallbladder cancer susceptibility and treatment outcome in a north indian population. Mol Diagn Ther. 19:317–327. 2015. View Article : Google Scholar : PubMed/NCBI |